|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||94.90 - 95.05|
|52-week range||73.31 - 114.80|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||17.77|
|Forward dividend & yield||3.52 (3.62%)|
|Ex-dividend date||06 May 2022|
|1y target est||123.28|
Shares of GSK and Sanofi surged on Wednesday, adding more than $20 billion in combined value in early trade following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer. The ruling on Tuesday by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocked out about 50,000 claims in federal court on the basis that they were not backed by sound science. The drugmakers, citing scientific consensus, have repeatedly asserted that Zantac does not cause cancer.
By Scott Kanowsky
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.